Immunological Profile of Solid Tumors Sample

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1040 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-06

Study Completion Date

2020-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented.

This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

NCT03706625

Non Hodgkin Lymphoma Non Small Cell Lung Cancer Glioma

COMPLETED

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

NCT04941365

Metastatic Melanoma Metastatic Breast Cancer Advanced Renal Cell Carcinoma +3 more

WITHDRAWN NA

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

NCT06365840

TMB-H Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

RECRUITING PHASE2

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100

Melanoma Advanced Melanoma

COMPLETED

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

NCT05276310

Advanced Cancer

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

biomarkers expression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

immunohistochemistry assay

biomarkers expression

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sample must have had a valid written informed consent for available archival tumor samples for scientific purposes.
* Sample from patients with histologically documented cancer in target population.